OPT 66
Latest Information Update: 03 Jul 2009
At a glance
- Originator Optimer Pharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action Glycoside hydrolase inhibitors; Hexosaminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 03 Jul 2009 Discontinued - Preclinical for Osteoarthritis in USA (unspecified route)
- 14 Jan 2003 Preclinical trials in Osteoarthritis in USA (unspecified route)